Close Window LIFE: The Losartan Intervention For Endpoint Reduction in Hypertension Study Bjorn Dahlof Disclosures: I do not consider that I have a conflict of interest in connection with this paper insofar as I do not believe that any relationships, competition, or commitments that I have, have biased my input into or objective judgment of this work. However I declare that I have served as a consultant and have had speaking engagements, not necessarily related to this topic, to most pharmaceutical companies, including the sponsor of this study, marketing CV drugs and have been compensated for travel, time spent on research and lectures.